Ustekinumab under the trade name Stelara (also known as CNTO 1275) is an immunosuppressant used to treat plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Ustekinumab as the first biologic therapy for Crohn’s disease is the only treatment for Crohn’s disease that starts with a weight-based, one-time intravenous (IV) infusion induction dose.
DMF, the methyl ester of fumaric acid, combined with three other fumaric acid esters (FAE) was licensed in Germany as an oral therapy for psoriasis under the trade name Fumaderm and Since 2013 it is used to treat adults with relapsing multiple sclerosis under the trade name Tecfidera.
Sovaldi (Sofosbuvir) is a direct-acting antiviral medication indicated for the treatment of Chronic Hepatitis C (CHC) infection. On the World Health Organization’s List of Essential Medicines, It is the most effective and safe medicines needed in a health system.
Glatiramer acetate with the trade name “Copaxone” is a combination of four naturally amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine that affect the immune system. This unique multiple sclerosis immunomodulatory is the first innovative drug that is developed in Israel.
GRAN® (Filgrastim) is a human Colony-Stimulating Factor (G-CSF) that is produced by genetic recombination technology. Pegfilgrastim is a Pegylated form of GCSF (Analog Filgrastim ) manufactured by Amgen (U.S.) and Kyowa Hakko Kirin (Japan).